Access the full text.
Sign up today, get DeepDyve free for 14 days.
T. Anderson (2009)
Novartis under fire for accepting new reward for old drugThe Lancet, 373
P. Doshi (2014)
US incentive scheme for neglected diseases: a good idea gone wrong?BMJ : British Medical Journal, 349
P Doshi (2014)
US incentive scheme for neglected diseases., 349
(2014)
The high cost of rare disease drugs. Genetic Engineering and Biotechnology News. http://www.genengnews.com/insight-and -intelligence/the-high-cost-of-rare-disease-drugs /77900055/?kwrd=Aflibercept
J. Avorn (2013)
Approval of a tuberculosis drug based on a paradoxical surrogate measure.JAMA, 309 13
(2015)
FDA voucher for leishmaniasis treatment
This Viewpoint assesses the US Food and Drug Administration’s priority review voucher program to encourage development of drugs to treat neglected tropical diseases or rare pediatric disease and recommends improvements to the program.
JAMA – American Medical Association
Published: Oct 27, 2015
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.